GLENMARK

strengthens its US generics portfolio 💊

US subsidiary has launched Epinephrine Injection USP (30 mg/30 mL, 1 mg/mL) Multiple-Dose Vial in the US market. The product is bioequivalent and therapeutically equivalent to BPI Labs’ reference drug, enabling Glenmark to compete directly in a regulated, high-entry-barrier injectable segment. As per IQVIA data, the product addresses a US market with ~$67.6 million in annual sales (12 months ending October 2025). While not a blockbuster, injectables typically offer better pricing power, stickier demand, and lower competitive intensity compared to oral solids. Strategically, this launch highlights Glenmark’s continued focus on complex generics and hospital injectables in the US — a segment that supports margin stability and diversifies revenue streams amid pricing pressure in conventional generics. Incremental revenue, strong portfolio depth, and long-term US presence strengthening.